Clinical Safety Profile of TrichoConcept™, a Line of Cosmetic Vehicles for Personalized Treatment of Alopecia.

Q4 Medicine International journal of pharmaceutical compounding Pub Date : 2024-03-01
Bruna Marianni, Hudson Polonini, Carolina Silva
{"title":"Clinical Safety Profile of TrichoConcept™, a Line of Cosmetic Vehicles for Personalized Treatment of Alopecia.","authors":"Bruna Marianni, Hudson Polonini, Carolina Silva","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Alopecia is a chronic dermatological disorder that affects patients worldwide, with a significant impact on quality of life, self-esteem, and psychological wellbeing. However, commercially available options for alopecia treatment are still limited. Considering that topical formulations have a long-term use therapeutic profile, the safety of their ingredients should be closely evaluated to avoid potentially irritant substances. Alternative active ingredients with different mechanisms of action, as well as adequate vehicles, might increase patients' adherence leading to better clinical outcomes. The purpose of this study was to examine the irritation, skin sensitization, photoallergy, and phototoxicity potential of a line of ready-to-use vehicles for producing topical therapies for alopecia treatments, TrichoConcept™. Subjects were selected and randomly assigned to compare the patch test with the study products or to the control solution (sterile 0.9% NaCl solution). No clinical signs of irritation, sensitization, photoallergy or phototoxicity were reported. From the results of this study, it is suggested that the investigated products can be considered safe under the evaluated conditions, and the claims \"dermatologically tested\", \"clinically tested\", and \"nonirritant\" can be supported.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of pharmaceutical compounding","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Alopecia is a chronic dermatological disorder that affects patients worldwide, with a significant impact on quality of life, self-esteem, and psychological wellbeing. However, commercially available options for alopecia treatment are still limited. Considering that topical formulations have a long-term use therapeutic profile, the safety of their ingredients should be closely evaluated to avoid potentially irritant substances. Alternative active ingredients with different mechanisms of action, as well as adequate vehicles, might increase patients' adherence leading to better clinical outcomes. The purpose of this study was to examine the irritation, skin sensitization, photoallergy, and phototoxicity potential of a line of ready-to-use vehicles for producing topical therapies for alopecia treatments, TrichoConcept™. Subjects were selected and randomly assigned to compare the patch test with the study products or to the control solution (sterile 0.9% NaCl solution). No clinical signs of irritation, sensitization, photoallergy or phototoxicity were reported. From the results of this study, it is suggested that the investigated products can be considered safe under the evaluated conditions, and the claims "dermatologically tested", "clinically tested", and "nonirritant" can be supported.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于个性化治疗脱发的化妆品载体 TrichoConcept™ 的临床安全性简介。
脱发是一种慢性皮肤病,影响着全世界的患者,对生活质量、自尊和心理健康都有重大影响。然而,市面上治疗脱发的药物仍然有限。考虑到外用制剂具有长期使用的治疗特性,应密切评估其成分的安全性,以避免潜在的刺激性物质。具有不同作用机制的替代活性成分以及适当的载体可能会提高患者的依从性,从而获得更好的临床疗效。本研究的目的是检测 TrichoConcept™ 系列即用型载体的刺激性、皮肤致敏性、光过敏性和光毒性潜力,这些载体可用于生产脱发治疗的外用疗法。受试者经挑选后随机分配,与研究产品或对照溶液(无菌 0.9% 氯化钠溶液)进行贴片测试比较。没有关于刺激、过敏、光过敏或光毒性的临床症状报告。研究结果表明,在评估条件下,研究产品是安全的,"经皮肤学测试"、"经临床测试 "和 "无刺激 "的说法是成立的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
62
期刊介绍: The International Journal of Pharmaceutical Compounding (IJPC) is a bi-monthly, scientific and professional journal emphasizing quality pharmaceutical compounding. IJPC is the only publication that covers pharmaceutical compounding topics relevant and necessary to empower pharmacists to meet the needs of today"s patients. No other publication features hands-on, how-to compounding techniques or the information that contemporary pharmacists need to provide individualized care.
期刊最新文献
Acute Migraine Treatment with Timolol 0.5% Nasal Spray - Compounding Pharmacists Have an Important Role. Basics of Compounding: Tips and Hints, Part 4: Lollipops/Lozenges, Gummy Bears, Patches, Flavoring/Coloring, Sweeteners, and Packaging. Combination Therapy of Oral LDN and Topical Pentoxifylline, Rifampin, Clindamycin for Hidradenitis Suppurativa. Compounding Trade Association Issues Ketamine, Office Pay Best Practices APC Also Updated Position Statements on Constructive Transfer and Peptide Compounding. Extended Chemical and Microbial Stability of Various Hormones in Phytobase and HRT Heavy Cream Bases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1